Celcuity is moving higher as traders continue to bid up the stock around its lead drug candidate, gedatolisib, ahead of a key FDA decision window. Recent company updates have highlighted that the FDA accepted its New Drug Application and that the application is under Priority Review with a July 17, 2026 goal date, keeping the name squarely in “catalyst trade” mode as the PDUFA approaches. (ir.celcuity.com)

The rally has also been supported by a more constructive sell-side setup following a recent price-target increase to $125 while maintaining a Buy rating, tied in part to updated expectations around operating expense and program timing. That incremental optimism has helped keep dip-buyers active as the market looks through near-term losses toward a potential U.S. launch scenario later in 2026 if the drug is approved. (investing.com)

CELC has been printing new highs in recent sessions, and today’s gain looks consistent with momentum/technical buying where fresh-high breakouts can trigger systematic flows and short covering. With the next major biotech-specific catalyst still ahead, price action can remain sensitive to any incremental regulatory, clinical-trial-timing, or commercial-readiness details that shift perceived odds into the PDUFA date. (marketbeat.com)